Episode 59: ASM Roundup - Day 2 with Dr. Marinka Twilt and Dr. Mo Osman

Hosts: Dr. Daniel Ennis, Dr. Janet PopeGuests: Dr. Marinka Twilt (Pediatric Rheumatologist, University of Calgary; ASM Program Committee Chair), Dr. Mo Osman (University of Alberta; Abstract Chair & ASM Planning Committee Co-Chair)We’re coming to you almost live from Halifax for Day 2 of the Canadian Rheumatology Association ASM. The day featured diverse podium science, practical workshops, and a lively Great Debate on DMARD tapering.Podium sessions highlighted lupus research on cancer risk, rising costs and work disability in RA, and new biologic insights into flares, with B-cell changes supporting patient-reported disease activity in lupus.Workshops focused on practical tools, including capillaroscopy for early CTD detection, pediatric updates on neonatal lupus risk (anti-Ro vs anti-La), and a structured lab-based approach to unexplained lymphadenopathy.The Dunlop-Dottridge Lecture reviewed statin-associated myositis, emphasizing delayed onset, persistence after discontinuation of the statins, and early IVIG-based treatment.The Great Debate explored DMARD tapering, reinforcing that while guidelines are cautious, real-world care requires shared decision-making and a focus on the lowest effective dose rather than full discontinuation.Main TakeawaysRising costs and ongoing work disability remain significant in RAPatient-reported flares have a clear biological basisStatin-associated myositis can occur years after statin use and requires early IVIGDMARD tapering should be individualized, with focus on lowest effective doseWhat to Watch for on Day 3State-of-the-art lecture on Still’s disease across the lifespanMore high-impact podium presentationsClinical workshops, including one on topical therapiesGala dinner and closing eventsMore highlights coming tomorrow—stay tuned!